Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2018-03-24 12:46 CET (UTC+1h)

95% Upper bound calculation [RSABE / ABEL]

posted by Katrin_Ti - Austria, 2018-03-13 09:31  - Posting: # 18526
Views: 182


as the guidence for acyclovir creams defines:

The replicate skin sections from donor 1 dosed with the test product may be denoted as T11,
T21, ..., Tr1, and likewise from donor 2, T12, T22, ..., Tr2, and so forth up to n donors; T1n,
T2n, ..., Trn. Similarly, the replicate skin sections dosed with the RLD product may be denoted as R1n, R2n, ..., Rrn.

That means that you need the same number of replicates from each donor (for R and T) for further calculations.

Calculate the point estimate, inter-donor variability and within reference variability using the log-transformed data (as defined in the acyclovir cream guidance).
If SWR >= 0.294 use the RSABE approach and calculate the upper bound of the CI as described in the Progesterone guidance.
I think the SAS code described in the progesterone guidance has to be modified but I can not help you with this task.


Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
18,075 Posts in 3,845 Threads, 1,140 registered users;
41 users online (0 registered, 41 guests).

It is better to be wrong than to be vague.
In trial and error, the error is the true essential.    Freeman Dyson

BEBAC Ing. Helmut Schütz